KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation

Παρόμοια τεκμήρια

• Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
  ανά: Hodi, F. Stephen, κ.ά.
  Έκδοση: (2013)
• KIT Gene Deletions at the Intron 10−Exon 11 Boundary in GI Stromal Tumors
  ανά: Corless, Christopher L., κ.ά.
  Έκδοση: (2004)
• Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
  ανά: Serrano, César, κ.ά.
  Έκδοση: (2019)
• Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
  ανά: Serrano, César, κ.ά.
  Έκδοση: (2019)
• Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors
  ανά: Liu, Feiyang, κ.ά.
  Έκδοση: (2019)